Study #2021-0684
Phase II Trial of Immunotherapy in Patients with Carcinomas Arising from the Renal Medulla.
MD Anderson Study Status
Not Accepting
Treatment Agent
Nivolumab, Relatlimab
Description
To learn if the combination of nivolumab and relatlimab can help to control renal medullary carcinoma (RMC) that is locally advanced or metastatic (has spread).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Carcinomas, Renal Medullary Carcinoma
Study phase:
Phase II
Physician name:
Pavlos Msaouel
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-855-927-2548
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.